HC Wainwright Predicts Increased Earnings for Urogen Pharma

Urogen Pharma (NASDAQ:URGN) – Equities research analysts at HC Wainwright raised their Q3 2027 earnings per share estimates for shares of Urogen Pharma in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.36 for the quarter, up from their prior estimate of $0.28. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2027 earnings at $0.50 EPS.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million.

URGN has been the subject of several other research reports. Oppenheimer increased their price objective on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Guggenheim increased their price target on Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a report on Thursday. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $44.00 price objective on shares of Urogen Pharma in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.78.

Urogen Pharma Trading Down 1.8%

URGN stock opened at $45.60 on Friday. The stock has a 50-day moving average price of $36.07 and a two-hundred day moving average price of $26.98. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $48.03. The company has a market cap of $2.22 billion, a PE ratio of -23.03 and a beta of 1.57.

Institutional Trading of Urogen Pharma

Several institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its holdings in shares of Urogen Pharma by 347.5% in the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after buying an additional 88,577 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares during the period. Jane Street Group LLC raised its stake in Urogen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after acquiring an additional 24,839 shares during the period. Cetera Investment Advisers bought a new position in Urogen Pharma in the second quarter worth about $361,000. Finally, JPMorgan Chase & Co. lifted its holdings in Urogen Pharma by 5.2% in the second quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock worth $5,348,000 after acquiring an additional 19,405 shares during the last quarter. Institutional investors own 91.29% of the company’s stock.

Insider Activity

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider owned 119,763 shares in the company, valued at $4,790,520. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 25,222 shares of company stock valued at $892,661. Corporate insiders own 4.80% of the company’s stock.

Key Urogen Pharma News

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $75 from $45 and reiterated a Buy rating. The new target implies approximately 64.5% upside from the referenced $45.60 price, signaling increased analyst confidence in Urogen’s commercial outlook. Benzinga The Fly
• Positive Sentiment: Second-quarter revenue was $72.46 million, above the $63.55 million analyst estimate. The company reported $50.4 million in ZUSDURI revenue, providing evidence of meaningful commercial traction and supporting the bullish analyst view. Urogen second-quarter financial results
• Neutral Sentiment: Management discussed the second-quarter results and company outlook during its earnings call, which investors may use to assess ZUSDURI’s sales trajectory, operating plans, and path toward profitability. Urogen Q2 2026 earnings call transcript
• Negative Sentiment: Urogen reported a quarterly loss of $0.28 per share, slightly worse than the $0.26 consensus estimate. Although the loss improved substantially from $1.05 per share a year earlier, continued losses and the EPS miss may be prompting profit-taking after the stock’s sharp run-up. Urogen earnings report

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.